News

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...
Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...
Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...